Table 2.
Incidence of most commonly reported adverse events
| Treatment | Placebo | |
|---|---|---|
|
Frovatriptan 2.5 mg QD |
n=501 |
n=505 |
| Nausea |
4.80% |
3.40% |
| Headache |
4.60% |
6.30% |
| Dizziness |
3.60% |
2.60% |
| Nasopharyngitis |
3.20% |
2.40% |
| Dysmenorrhea |
2.20% |
3.00% |
|
Frovatriptan 2.5 mg BID |
n=501 |
n=505 |
| Nausea |
6.80% |
3.40% |
| Dizziness |
4.80% |
2.60% |
| Headache |
4.20% |
6.30% |
| Nasopharyngitis |
3.40% |
2.40% |
| Dysmenorrhea |
1.80% |
3.00% |
|
Naratriptan 1 mg BID |
n=71 |
n=68 |
| Dyspeptic symptoms |
4.23% |
0.00% |
| Malaise and fatigue |
1.41% |
2.94% |
| Dizziness |
1.41% |
1.47% |
| Hyposalivation |
1.41% |
0.00% |
| Parasthesia |
1.41% |
0.00% |
|
Naratriptan 2.5 mg BID |
n=71 |
n=68 |
| Dizziness |
4.23% |
1.47% |
| Chest symptoms |
2.82% |
2.94% |
| Malaise and fatigue |
2.82% |
2.94% |
| Hyposalivation |
2.82% |
0.00% |
| Parasthesia |
2.82% |
0.00% |
| Burning/stinging sensations |
2.82% |
0.00% |
|
Zolmitriptan 2.5 mg BID |
n=80 |
n=82 |
| Asthenia |
8.75% |
9.76% |
| Dizziness |
6.25% |
4.88% |
| Somnolence |
6.25% |
3.66% |
| Nausea |
6.25% |
1.22% |
| Tightness |
5.00% |
2.44% |
| Headache |
3.75% |
2.44% |
| Dry mouth |
1.25% |
1.22% |
|
Zolmitriptan 2.5 mg TID |
n=84 |
n=82 |
| Asthenia |
10.71% |
9.76% |
| Headache |
8.33% |
2.44% |
| Dizziness |
7.14% |
4.88% |
| Somnolence |
7.14% |
3.66% |
| Tightness |
7.14% |
2.44% |
| Nausea |
7.14% |
1.22% |
| Dry mouth | 5.95% | 1.22% |